利伐沙班与华法林治疗下肢深静脉血栓的临床效果对比

Rivaroxaban vs. Warfarin for the treatment of lower extremity deep vein thrombosis

目的分析比较利伐沙班与华法林治疗下肢深静脉血栓（DVT）的临床效果。方法回顾性分析2015年1至12月门诊确诊为下肢深静脉血栓且资料完整的51例患者，根据其所采取的治疗方案分为华法林组（21例）和利伐沙班组（30例），治疗时间≥3个月。分别对两组患者的年龄、性别、病史、血栓部位及血栓再通情况等进行分析。结果利伐沙班组患者的用药时间较华法林短，治疗结束时两组患者的静脉通畅率（85.7%比60.0%）利伐沙班组高于华法林组（均P〈0.05），华法林组的5例混合型静脉血栓患者在治疗结束时其下肢静脉彩超显示均为部分再通，而利伐沙班组5例混合型静脉血栓患者2例患者静脉血栓完全消除，3例部分再通。周围型静脉血栓完全再通率利伐沙班组高于华法林组（84%比25%，P〈0.05）。结论利伐沙班能显著提高下肢深静脉血栓患者的静脉通畅率和再通率。

Objective To compare the clinical efficacy of Rivaroxaban and Warfarin in the treatment of lower extremity deep vein thrombosis. Methods From January to December 2015,51 patients of deep vein thrombosis of the lower limb divided into. Warfarin group （21 cases） and Rivaroxaban group （30 cases） . The time of each therapy lasted for 3 months or longer. The characteristics and the change of lower limb venous patency rate in two groups of patients were analyzed to evaluate the curative effect. Results Rivaroxaban group had shorter therapy time than Warfarin group. The lower limb venous patency rate in Rivaroxaban group were higher than that in Warfarin group （85.7% vs. 60% ,P 〈 0. 05 ）. Ultrasonography showed partial patency in 5 mixed thrombus patients of Warfarin group , while complete patency in 2 and partial patency in 3 of Rivaroxaban group. Normalized rate in peripheral venous thrombosis patients of Rivaroxaban group were higher than Warfarin group （ 84% vs. 25% P 〈 0. 001 ）. Conclusions Rivaraxaban is superior to Warfarin in the complete recanalization of DVT,while safe and reliable.